Updated on 19 February 2014
Dr Ray Dorsey, professor, neurology, University of Rochester, and principal investigator on the trial added, "We are very pleased that the results of the Reach2HD study have shown that PBT2 is well tolerated and generally safe over six months in individuals with early to mid-stage Huntington disease."
"In addition, the results indicated a significant benefit on cognition that is consistent with the previous trial in Alzheimer's disease and is accompanied by an encouraging finding in functional capacity. We are very thankful for the involvement of the research participants and investigators in this study and look forward to future trials of this promising therapy for one of the cardinal features of Huntington disease."
Prana plans to advance PBT2 into a confirmatory phase III clinical trial that could allow PBT2 to be approved for the treatment of Huntington disease.